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Introduction
The introduction of monoclonal antibody in the manage-
ment of Colorectal Cancer (CRC) in the rapidly rising
healthcare cost environment prompt a proper evaluation
of its cost effectiveness especially to the local setting. The
rising incidence of CRC in Malaysia also justifies a detailed
evaluation on its economic impact. This study aims to
determine the cost of CRC management and to compare
the cost effectiveness of monoclonal antibody with con-
ventional chemotherapy in the management of CRC.
Methods
This economic evaluation study was performed from the
societal perspective. It involves collecting resource utiliza-
tion data based on clinical pathway of colorectal cancer
management. Cost calculated included cost of drugs,
human resources, administrative, investigations as well as
capital cost. Direct and indirect patient’s cost were also
calculated based on interview with CRC patients. CRC
patients’ quality of life were measured using EORTC
QLQ-C30 questionnaire and effectiveness estimates for
monoclonal antibody (Cetuximab and Bevacizumab) treat-
ment were modeled from study respondents based on
references from other studies. One way sensitivity analysis
was used to determine the robustness of the result.
Result
A total of 160 respondents were involved in the study with
the mean age of 58.47 (SD 12.04) years. The average cost
of treating a case of colorectal cancer is RM 22,833.44
(RM 18,818.53 - RM 26,848.35). Cost of CRC management
increased with increasing stage of the disease (Kruskal
Wallis, X2 = 106, p < 0.001). Incremental cost per life
years gained is RM 118,366.37 for Cetuximab and RM
61,584.68 for Bevacizumab. Incremental cost per quality
adjusted life years gained for Cetuximab is RM 67,063.83
and RM 34,892.47 for Bevacizumab. Although both types
of monoclonal antibody are considered cost effective
(based on WHO guideline of less than 3 times of GDP),
Bevacizumab is considered more cost effective than Cetux-
imab. Sensitivity analysis shows that, cost effectiveness was
sensitive to the percentage of late stage of CRC.
Conclusion
Monoclonal antibody especially Bevacizumab is more cost
effective in the management of late stage of CRC. There-
fore it should be considered to be used in the CRC as a
combination with the current chemotherapy treatment for
CRC. The country should invest to the administration of
monoclonal antibody to CRC treatment.
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